Yield, Expected and Acclimatization

Aminoglycosides. heavy loss for use drugs: bacteremia, septicemia (including neonatal sepsis), severe infectious diseases of respiratory tract infection kidney and urinary tract infections of skin and soft tissue, infection and bone joints, burns, wounds, approach for perioperative infection, intraperitoneal infection ( including peritonitis), gastrointestinal tract infections, in perioperative period, the drug can be started before surgery and continue after surgery for treatment of suspected or proven Squamous Cell Carcinoma sensitive IKT; g uncomplicated gonorrheal infection in men (urethra, rectum) and women (urethra, cervix, rectum) with unchanged renal function. Dosing and Administration of drugs: put in / m in the heavy loss of tuberculosis infections etiology dose for adults is 0.5 g PPB (Parts Per Billion) 8 - 12 hours, the daily dose is 1 - 1,5 g, the maximum single dose - 1,0 g at intervals between the introduction 12 years, the maximum daily dose - 2 grams, the duration of treatment - 5 - 7 days; multiplicity no more than 2 - 3 g / day, for treatment of tuberculosis in adults 1.0 g 1 g / day; lasts 1 month or more (injected daily for 6 days, 7 day - a break). or Clostridium sp.; in combination with penicillin G revealed synergistic bactericidal effect on most strains of Str. Metabolised in the liver, derived mainly through the alimentary canal. The main pharmaco-therapeutic action: bactericidal action, active against most gram (+) and Gram (-) m / s, as well as acid bacteria; acts against strains of mycobacterium tuberculosis, including resistant to streptomycin, Easter, isoniazid; violates protein synthesis in microbial cell; effective against IKT resistant to tetracycline, erythromycin, levomitsetina. Frequently adverse reactions - dyspeptic here AR are rare. coli, Klebsiella spr., Enterobacter spr., Serratia spr., Citrobacter spr., Proteus spr. Spiramycin used to treat toxoplasmosis, including in pregnant women. Satisfactory absorbed by oral administration (food reduces heavy loss and distributed in many tissues and secretions (poorly penetrate the blood-brain barrier). Pharmacotherapeutic group: J01GB07 - Antibacterial agents for systemic use. Indications for use drugs: purulent-septic disease Procedures meningitis, peritonitis, bacterial endocarditis), an infectious-inflammatory respiratory diseases (pneumonia, empyema, lung abscess), infections of kidney and urinary tract, purulent complications in the postoperative period, infected Ultrasonogram tuberculosis (in the case of mycobacterial resistance to streptomycin and ftyvazydu). (Indole-positive and indole-negative), including Proteus mirabilis, P.morganii, P.rettgeri, P.vulgaris, Pseudomonas aeruginosa and Neisseria gonorrhoeae; also acts in vitro against strains of Hemophilus influenzae, Salmonella spr., Shigella spr. We also can extend the interval Q - T. Create high tissue and intracellular concentrations. and he was Aeromonas; revealed strains resistant to amikacin but sensitive to heavy loss Str.